clinical trial · NCT04660344
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
Muscle-invasive Bladder CancerAtezolizumabPlaceboSignatera
brief summary
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.
started
May 3, 2021
primary completion
Jun 15, 2025
completion
Oct 1, 2026
last updated
Sep 28, 2026
official title
A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol